Skip to main content

Table 1 Patient baseline characteristics

From: Association of left atrial strain by cardiovascular magnetic resonance with recurrence of atrial fibrillation following catheter ablation

  Overall n = 80 No AF recurrence n = 59 AF recurrence n = 21 p-value
Demographics
 Age, mean ± SD 58.6 ± 9.4 58.5 ± 11.5 58.6 ± 8.9 0.99
 Male 60 (75) 42 (71.2) 18 (85.7) 0.2
 Caucasian 76 (95) 54 (91.5) 21 (100) 0.64
 Prior DC cardioversion 29 (36.3) 23 (39) 6 (28.6) 0.2
Comorbidities
 Current/former smoker 20 (25) 16 (27.1) 4 (19) 0.29
 Coronary artery disease 10 (12.5) 9 (15.3) 1 (4.8) 0.16
 Peripheral arterial disease 1 (1.25) 0 1 (4.8) 0.12
 Heart failure 8 (10) 7 (11.9) 1 (4.8) 0.28
 Hypertension 38 (47.5) 27 (45.8) 11 (52.4) 0.92
 Obstructive sleep apnea 18 (22.5) 11 (18.6) 7 (33.3) 0.33
 Diabetes mellitus 3 (3.8) 3 (5.1) 0 0.27
 Cerebrovascular disease 1 (1.25) 1 (1.7) 0 0.53
CHA2DS2-VASc score
 0 22 (27.5) 16 (27.1) 6 (28.6) 0.79
 1 32 (40) 21 (35.6) 11 (52.4) 0.45
 2 16 (20) 13 (22) 3 (14.3) 0.30
  ≥ 3 10 (12.5) 7 (11.9) 3 (14.3) 0.61
Medications
 Aspirin 17 (21.3) 11 (18.6) 6 (28.6) 0.57
 Statin 29 (36.3) 1 (1.7) 2 (9.5) 0.15
 Warfarin 9 (11.3) 7 (11.9) 2 (9.5) 0.62
 Apixaban 12(15) 9 (15.3) 3 (14.3) 0.73
 Rivaroxaban 35(43.8) 23 (39.0) 12 (57.1) 0.43
 Dabigatran 4 (5) 3 (5.1) 1 (4.8) 0.85
 Beta Blocker 55 (68.8) 40 (67.8) 15 (71.4) 0.52
 Calcium channel blocker 22 (27.5) 18 (30.5) 4 (19) 0.18
 Anti-Arrhythmic Therapy 45 (56.3) 32 (54.2) 13 (61.9) 0.33
 Flecanaide 17 (21.3) 10 (16.9) 7 (33.3) 0.25
 Propafenone 4 (5) 3 (5.1) 1 (4.8) 0.85
 Sotalol 4 (5) 1 (1.7) 3 (14.3) 0.04
 Amiodarone 4 (5) 4 (6.8) 0 0.20
 Dronderone 14 (17.5) 11 (18.6) 3 (14.3) 0.48
 ACE/ARB 22 (27.5) 19 (32.2) 3 (14.3) 0.06
 Levothyroxine 7 (8.8) 4 (6.8) 3 (14.3) 0.42
 Diuretic 14 (17.5) 11 (18.6) 3 (14.3) 0.48
  1. Significant p-values are shown in bold
  2. ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DC, direct current